No Stock Yet
No Stock Yet
Announcement selection | the annual net profit of Zhaoyan new drug has increased by more than 72%; China Longyuan Power Group Corporation's annual return net profit has increased by more than 25% compared with the same period last year.
Tencent spent about HK $200m on buybacks yesterday; three major telecom operators released December operating data; China Life Insurance Company Limited and the group company plan to increase capital to property insurance companies by 9 billion yuan; China Evergrande Group suggested hiring more CICC as legal advisers to help resolve debt risks.
Li Ankang, CFO&CSO: I am interested in the changes in the central nervous system and infection.
Source: medicine Rubik's Cube JP Morgan Health Industry Conference (JP Morgan Healthcare Conference) is an annual event with a close combination of industry and capital: large pharmaceutical companies present their business development strategies to global investors, while many high-quality small biomedical companies are looking for partners with their projects. Executives of the world's leading pharmaceutical companies / Biotech, investment banks, consulting firms, accounting firms, law firms and other institutions used to fly from all over the world to San Francisco like migratory birds at the beginning of January. This year's JPM conference was affected by the epidemic.
Tengsheng Bo Pharmaceutical-B (02137.HK) rose 10.47%.
[Caihua Social News] Tengsheng Bo Drug-B (02137.HK) rose 10.47% as of 10:00 to HK $24.8, or HK $2.35. 2.15 million shares were traded, involving 51.21 million yuan. (source: FinetAI)
Biomedical sector strengthened Nuohui Health (06606) rose 14.77%
Phoenix New Media Hong Kong stocks | Biopharmaceutical sector is strong, Nuohui Health (06606) is up 14.77%, Goliath Pharmaceutical (01672) is up 10.84%, Tengshengbo Pharmaceutical (02137) is up 5.12%, Development Pharmaceutical (09939) is up 2.41%, and Peijia Medical (09996) is up 2.09%. On the news side, according to Alibaba Health Information Technology, Nuohui health product claustrophobia will be put on the market on January 18, 2022. The YouTube is the first consumer self-test product of Helicobacter pylori approved by the State Drug Administration, which realizes the integrated design of sampling and testing.
Tengsheng Bo Pharmaceutical-B (02137.HK) fell 3.62%.
[Caihua Social News] Tengsheng Bo Drug-B (02137.HK) fell 3.62% as of 14:13 to HK $21.30, or HK $0.80. 4.76 million shares were traded, involving 100.8 million yuan. (source: FinetAI)
Afternoon comment on Hong Kong stocks | the Hang Seng Technology Index is down 0.58%, Ariel is up more than 3%, and JD.com is up more than 2%.
The Hang Seng Index fell 0.36%. Among technology stocks, Baidu, Inc. and Meituan rose slightly, Tencent and XIAOMI fell slightly, and Kuaishou Technology fell nearly 4%. Machinery stocks, building materials stocks and cement stocks rose, while Chinalco International rose nearly 34%. Film and television entertainment stocks, gambling stocks, and traditional Chinese medicine stocks strengthened, while medical and beauty concept stocks and tobacco concept stocks fell.
[new changes] Tengshengbo-B (02137) rose by nearly 7%. Recent phase 2a/2b clinical trial of chronic hepatitis B completes administration of the first patient.
Phoenix New Media Hong Kong stock | Tengsheng Boyao-B (02137) continued its rise yesterday, rising 6.98% to HK $33.70 with a turnover of HK $31.96 million as of press time. On the news side, the company recently announced that the company has completed the first patient administration in the BRII-179 (VBI2601) 2a/2b phase clinical trial of chronic hepatitis B virus (HBV) patients. It is estimated that 290 million people worldwide suffer from chronic HBV infection, and nearly 800000 people die each year from complications such as HBV-related liver cirrhosis, liver failure and liver cancer. BRII-179 (VBI
[new changes] Tengshengbo-B (02137) rose 11.49%. Recent phase 2a/2b clinical trial of chronic hepatitis B completes administration of the first patient.
Phoenix New Media Hong Kong stock | Tengsheng Boyao-B (02137) shares rose in shock today, rising 11.49% to HK $33 with a turnover of HK $41.36 million as of press time. It is reported that the company recently announced that the company has completed the first patient administration in the BRII-179 (VBI2601) 2a/2b phase clinical trial of chronic hepatitis B virus (HBV) patients. It is estimated that 290 million people worldwide suffer from chronic HBV infection, and nearly 800000 people die each year from complications such as HBV-related liver cirrhosis, liver failure and liver cancer. BRII-179 (VBI-26
Hong Kong stocks scan | Pork concept stocks soared collectively, Yurun Foods rose by more than 36%, and Cofco Jiakang rose nearly 13%.
Some education stocks have bucked the trend and hope that education will rise by nearly 7%, China Education Holdings and New Oriental Education & Technology Group online by nearly 5%, and China Science Education and New higher Education Group by nearly 3%.
Omicron virus is rampant all over the world, but the biological stocks of vaccines listed in Hong Kong are sold along with the outside industry.
The COVID-19 variant of Omicron is raging around the world, with a record number of confirmed cases in the United States, causing thousands of schools in the United States to delay returning to school or switching to distance learning. The US Food and Drug Administration (FDA) authorized children aged 12 to 15 to be vaccinated with Pfizer Inc (PFE.US) and BioNTech (BNTX.US) to provide a third dose of COVID-19 vaccine. BioNTech shares fell 10.1% to close at $231.85 last night, but Pfizer Inc lost more than 4% to close at $56.65 last night. Another vaccine stock, MRNA.US, fell 7.5% to close at 235.